YOUR SEARCH FOR Text 165 RESULTS
51 of Total
Microsoft Word - Incyte Compliance Program for CA Final Nov 2011.doc
… … Microsoft Word - Incyte Compliance Program for CA …
52 of Total
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido
… … Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido …
53 of Total
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatm
… … Incyte Announces the European Commission …
54 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
… third quarter of 2025, reflecting 20% growth compared to the third quarter of 2024 Jakafi ® … and effective commercial execution,” said Bill Meury , President and Chief Executive Officer, …
55 of Total
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results | Incyte
… growth and pipeline progress,” said Bill Meury , President and Chief Executive Officer, … revenue was $1.51 billion , an increase of 28% compared to the fourth quarter of 2024, …
56 of Total
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… now also approved in Europe and Japan, becoming the first internally discovered product … academic and community physicians,” stated Hervé Hoppenot, Chief Executive Officer, Incyte. “We …
57 of Total
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… patients treated with ruxolitinib cream; Company pursuing regulatory approvals in the … diversifying and growing our revenue,” said Hervé Hoppenot, Chief Executive Officer, Incyte. …
58 of Total
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… results, and provides a status update on the Company’s clinical development portfolio. “Our … long-term growth driver for Incyte,” said Hervé Hoppenot , Chief Executive Officer, Incyte . …
59 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… financial guidance and a status update on the Company’s clinical development portfolio. “2021 … cream in atopic dermatitis,” said Hervé Hoppenot , Chief Executive Officer, Incyte . …
60 of Total
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… - Positive CHMP opinion for tafasitamab in combination with lenalidomide for the treatment … growth opportunity for Incyte,” stated Hervé Hoppenot, Chief Executive Officer, Incyte. “We …